JUN 10, 2019 08:44 AM PDT

New discovery sheds light for precision medicine in cancer

A recent study published in Cancer Research highlights findings of a molecular indicator that could provide a new way for doctors to help predict how patients will respond to certain anticancer drugs. The research comes from scientists at Université de Montreal and could pave the way for novel methods of precision medicine.

The molecular indicator is composed of a group of enzymes called SRC kinases, which work to chemically modify a tumor-suppressing protein called SOCS1.

"SOCS1 is part of a gene-regulation circuit centered around the master cell proliferation regulator p53, often called the guardian of the genome," said senior author Gerardo Ferbeyre, a biochemist from Université de Montreal. "If p53 or another protein in its network is mutated or becomes chemically modified in some abnormal way, a pattern of gene activation occurs that programs cells to proliferate without control, as occurs in cancers."

This may sound complex (it is), but what it means is that the authors discovered another way in which p53 can become unbalanced, which results in the proliferation of cancer cells. This discovery will help predict if an anticancer drug could be an effective treatment for a patient’s tumor.

Subburaj Ilangumaran, a Université de Sherbrooke biochemist on the study, explained: "This new mechanism for SOCS1 inactivation may actually represent a regulatory control that is hijacked by cancer cells. On a more fundamental level, our group's discovery -- that phosphorylation of SOCS1 acquires a new physical form -- opens the door to hitherto unknown ways of regulating SOCS1 functions. And this has implications for the treatment of autoimmune diseases and for anticancer immunity."

This discovery could pave the way for new methods of precision medicine in cancer. Photo: Pixabay

UdeM PhD student Emmanuelle Saint-Germain added, "We were able to detect phosphorylated SOCS1 in patients' samples with an antibody that we developed. The same antibody could be used to detect phosphorylated SOCS1 in a clinical setting, providing a way to decide whether SRC kinase inhibitors would be an effective treatment."

Sources: Science Daily, Cancer Research

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 20, 2019
Health & Medicine
JUN 20, 2019
A Rare and Potent Sea Fighter: An End to Melanoma Cells?
The researchers discovered a natural product, seriniquinone, derived from marine bacterium that can help kill the severe skin cancer cells or the melanoma cells....
JUN 20, 2019
Cell & Molecular Biology
JUN 20, 2019
Researchers Use Urine Cells to Create Kidney Organoids
These organoids be used for research and can be made from patient samples, as way to personalize the treatment....
JUN 20, 2019
Cancer
JUN 20, 2019
Why Breast Surgeons Are Calling for Wider Genetic Testing
In early 2019, the American Society of Breast Surgeons (ASBrS) released new recommendations on genetic testing for people with breast cancer, widening the ...
JUN 20, 2019
Drug Discovery
JUN 20, 2019
How a Cancer Drug Inhibits DNA Repair in Cancer Cells
In a study published in the journal Science Translational Medicine, combing a certain cancer drug with other agents could potentially deliver a lethal blow...
JUN 20, 2019
Drug Discovery
JUN 20, 2019
Tart Cherry and Pain Management in Breast Cancer Patients
In patients with non-metastatic breast cancer, treated with aromatase inhibitors, tart cherry was found to reduce the musculoskeletal effects of the drug. ...
JUN 20, 2019
Cancer
JUN 20, 2019
AI Improves Lung Cancer Detection in MIT Study
Lung cancer led to an estimated 160,000 deaths in 2018 in the U.S., making it the country’s leading cause of cancer-related deaths. Early detection c...
Loading Comments...